Cargando…

Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by memory loss and multiple cognitive impairments. Several decades of intense research have revealed that multiple cellular changes are implicated in the development and progression of AD, including mitochondrial damag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reddy, P. Hemachandra, Oliver, Darryll MA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562604/ https://www.ncbi.nlm.nih.gov/pubmed/31121890 http://dx.doi.org/10.3390/cells8050488

Ejemplares similares

Defective Autophagy and Mitophagy in Aging and Alzheimer’s Disease
por: Tran, Michael, et al.
Publicado: (2021)

Dynamics of Dynamin-Related Protein 1 in Alzheimer’s Disease and Other Neurodegenerative Diseases
por: Oliver, Darryll, et al.
Publicado: (2019)

Amyloid Beta in Aging and Alzheimer’s Disease
por: Sehar, Ujala, et al.
Publicado: (2022)

Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
por: Rawat, Priyanka, et al.
Publicado: (2022)

Amyloid Beta and MicroRNAs in Alzheimer’s Disease
por: Amakiri, Nnana, et al.
Publicado: (2019)

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
por: den Haan, Jurre, et al.
Publicado: (2018)

Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer’s Disease
por: Pradeepkiran, Jangampalli Adi, et al.
Publicado: (2019)

Are mitophagy enhancers therapeutic targets for Alzheimer’s disease?
por: Pradeepkiran, Jangampalli Adi, et al.
Publicado: (2022)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer’s Disease
por: Calkins, Marcus J., et al.
Publicado: (2012)

Mechanical Dilution of Beta-amyloid Peptide and Phosphorylated Tau Protein in Alzheimer's Disease: Too Simple to be True?
por: Menéndez González, Manuel
Publicado: (2017)

A partial reduction of VDAC1 enhances mitophagy, autophagy, synaptic activities in a transgenic Tau mouse model
por: Vijayan, Murali, et al.
Publicado: (2022)

The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
por: Yin, Xiaomin, et al.
Publicado: (2021)

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
por: Roda, Alejandro R., et al.
Publicado: (2022)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Defective mitophagy and the etiopathogenesis of Alzheimer’s disease
por: Zeng, Kuan, et al.
Publicado: (2022)

Neurobiological pathways to Alzheimer’s disease: Amyloid-beta, TAU protein or both?
por: de Paula, Vanessa de Jesus R., et al.
Publicado: (2009)

Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s disease
por: Burns, Lindsay H., et al.
Publicado: (2017)

Culprit or Bystander: Defective Mitophagy in Alzheimer’s Disease
por: Xie, Chenglong, et al.
Publicado: (2020)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
por: Lambracht-Washington, Doris, et al.
Publicado: (2013)

Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease
por: Lee, Ni-Chung, et al.
Publicado: (2017)

Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
por: Patow, Gustavo, et al.
Publicado: (2023)

Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus
por: Ali, Tahir, et al.
Publicado: (2015)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Compromised autophagy and mitophagy in brain ageing and Alzheimer’s diseases
por: Caponio, Domenica, et al.
Publicado: (2022)

Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease
por: Mullins, Roger J., et al.
Publicado: (2017)

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
por: Lue, Lih-Fen, et al.
Publicado: (2017)

JBPOS0101 regulates amyloid beta, tau, and glial cells in an Alzheimer’s disease model
por: Jeong, Jihoon, et al.
Publicado: (2020)

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease
por: Fan, Dong-Yu, et al.
Publicado: (2021)

Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer’s Disease Associated with Down Syndrome
por: Ichimata, Shojiro, et al.
Publicado: (2023)

Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer’s Disease
por: Sharma, Abhinav, et al.
Publicado: (2023)

New Treatment for Alzheimer's Disease, Kamikihito, Reverses Amyloid-β-Induced Progression of Tau Phosphorylation and Axonal Atrophy
por: Watari, Hidetoshi, et al.
Publicado: (2014)

Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches
por: Mary, Arnaud, et al.
Publicado: (2022)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Early Cellular, Molecular, Morphological and Behavioral Changes in the Humanized Amyloid-Beta-Knock-In Mouse Model of Late-Onset Alzheimer’s Disease
por: Kshirsagar, Sudhir, et al.
Publicado: (2022)

Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer’s Disease
por: Vijayan, Murali, et al.
Publicado: (2022)

Alzheimer’s Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia
por: Eshraghi, Mehdi, et al.
Publicado: (2021)

Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy
por: Mondragón-Rodríguez, Siddhartha, et al.
Publicado: (2012)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer’s Disease
por: Pickett, Eleanor K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ei5psidgf3v8ueg3aejbdqc0s8